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Previewsexpression in cancer may be yet another
possibility. For example, IL-11 is known
to be regulated by STAT3, oncogenic in-
sults, and hypoxia that are constantly
present in the tumor microenvironment,
thereby allowing prolonged IL-11 produc-
tion, whereas IL-6 production by immune
cells may be more tightly and spatially
regulated. A recent study suggests that
CAC tumorigenicity depends on IL-6R
produced by epithelium in mice with
altered colonic microbiota (Hu et al.,
2013). Adding to the mix, there are other
STAT3-activating cytokines beyond IL-6
and IL-11, such as IL-22, that also can
regulate CAC and CRC development
(Huber et al., 2012).
The work by Putoczki et al. (2013)
expands our understanding of the role
that cytokine-induced signaling plays in
cancer and warrants further examination
of the modalities of IL-11 inhibition in
various solid tumors. Given that another
recent study identified the IL-11/STAT3
pathway as a critical regulator of humanCRC invasion and metastasis (Calon
et al., 2012), it is safe to conclude that
IL-11 constitutes an important compo-
nent of the tumormicroenvironment, influ-
encing every step of tumorigenesis and
representing an attractive target for pre-
ventive and therapeutic approaches.
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The master regulator of the classical cytoprotective ‘‘heat shock’’ response, heat shock factor 1 (HSF1), is
increasingly implicated in cancer pathogenesis, but the mechanisms remain poorly understood. A recent
study connects increased protein translation to activation of HSF1 in malignant cells and demonstrates
the therapeutic benefit of targeting this link.It is fast becoming clear that the stress-
activated transcription factor heat shock
factor 1 (HSF1) is not only the master
regulator of the classical heat shock
response and ‘‘guardian of the prote-
ome,’’ but is also a key player in aging
and oncogenesis (Anckar and Sistonen,
2011). The well-known activation of
HSF1 by elevated temperature or other
acute proteotoxic stressors leads to
increased transcription of genes involved
in protein quality control, thereby allow-
ing cells to survive the stress. The
emerging role of HSF1 in oncogenesisis best exemplified by Hsf1-knockout
mice having reduced susceptibility to
tumorigenesis driven by oncogenic
Ras or mutant p53 (Dai et al., 2007).
Accumulation and activation of nuclear
HSF1 is triggered by diverse cellular or
environmental stresses associated with
cancer. These include proteotoxic stress
or oncogenic stress (Dai et al., 2012a,
2012b).
Recent research unexpectedly re-
vealed an HSF1 gene expression program
in cancer cells distinct from, though over-
lapping with, the transcriptional profilein the classical heat shock response
(Mendillo et al., 2012). The HSF1 cancer
program comprises not only genes
encoding proteins mediating proteostasis
and survival, but also those facilitating
invasion and metastasis, cellular prolifer-
ation, protein synthesis, and glucose
metabolism. Importantly, the HSF1 can-
cer gene signature correlates strongly
with metastasis and survival in breast,
colon, and lung cancer patients.
Despite recent progress, the precise
molecular details of how HSF1 is acti-
vated in cancer are poorly understood., August 12, 2013 ª2013 Elsevier Inc. 147
Figure 1. Linking Protein Translation to the HSF1 Transcriptional Response
Oncogenesis, such as that induced by the loss of NF1 or activation of RAS, induces protein synthesis by
increasing the activity of the translation machinery. This boost in protein synthesis induces, by a currently
unknown molecular mechanism (indicated by the blue ‘‘?’’), the binding of HSF1 to the promoter of the
cognate cancer-associated genes, thereby altering the transcription of these genes. The HSF1 cancer
program includes genes involved in energy metabolism, protein homeostasis, and protein translation.
Blocking translational initiation, exemplified by inhibition of EIF4A using rohibitin, reverts HSF1 activation
and switches off the HSF1 cancer program, resulting in the inhibition of the growth of cancer cells in vitro
and tumors in vivo.
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PreviewsNow, Santagata et al. (2013) report the
important discovery that regulation of
HSF1 transcriptional activity is tightly
linked to protein translation rate and sug-
gest a model in which HSF1 responds to
the enhanced protein production in
cancer by remodeling the transcriptional
program to support the anabolic malig-
nant state. Furthermore, they provide
proof of concept for reversing this pro-
cess with small-molecule inhibitors of
protein translation for potential therapeu-
tic application (Figure 1).
Santagata et al. (2013) used an inter-
esting chemical-genetic approach. First,
they conducted gene expression profiling
of breast cancer cells exposed to transla-
tion elongation inhibitors. The most
enriched mRNAs corresponded to genes
with promoters containing HSF1-binding
motifs, which were validated by promoter
occupancy analysis and include both
those associated with classical heat
shock and those in the HSF1 cancer
program. Thus, protein translation is
linked to HSF-1-mediated transcription
and oncogenesis.148 Cancer Cell 24, August 12, 2013 ª2013 ENext, the researchers determined a
gene signature of HSF1 silencing and
looked for close matches in a public data-
base. Best negative correlations were
with expression profiles for proteasome
and HSP90 inhibitors, validating the
approach because both activate HSF1.
Significantly, they also found the HSF1
knockdown gene signature to be posi-
tively correlated with the expression pro-
file of cells treated with protein translation
inhibitors and PI3K/mTOR inhibitors,
which are known to block translation.
Moreover, the most enriched gene
ontology classes seen are ribosomal sub-
unit proteins, translation initiation factors,
and aminoacyl tRNA synthetases. The re-
sults provide independent confirmation of
the connection between translational flux
and HSF1 function in cancer.
Santagata et al. (2013) then screened a
compound library looking for small mole-
cules that inhibited a cell-based HSF1 re-
porter selectively. The most potent and
selective hit identified was rocaglamide
A, a natural product of the flavagline class
that includes silvestrol. Silvestrol binds tolsevier Inc.the EIF4A RNA helicase, trapping it in a
complex with RNA and thereby impairing
the early stage of protein synthesis initia-
tion mediated by the EIF4F complex
(Sadlish et al., 2013). By screening ana-
logs, Santagata et al. (2013) identified an
even more potent synthetic inhibitor, rohi-
bitin. They showed that rohibitin does not
affect HSF1 levels, but blocks both HSF1
binding to DNA and the HSF1-regulated
gene expression program across histo-
logically diverse human cancer cell lines,
with lesser effects in non-tumorigenic
cells. Genes affected by rohibitin include
both classical heat shock genes and
genes specific to the HSF1 cancer pro-
gram, but not two control housekeeping
genes. These results identify rohibitin
as an upstream inhibitor of HSF1 activity
and once more confirm the connection
between HSF1 regulation and protein
translation in cancer.
Santagata et al. (2013) proceeded
to demonstrate that rohibitin inhibits
glucose uptake and reverts the cancer-
associated aerobic glycolysis (‘‘Warburg
effect’’) characteristic of cancers, which
is already associated with HSF1. These
metabolic changes were attributed to
the transcriptional modulation of HSF1-
regulated genes directly known to control
energy metabolism.
Seeking more defined therapeutic con-
texts, Santagata et al. (2013) assessed
the sensitivity to rohibitin using isogenic
models with different oncogenic lesions.
They found rohibitin to be more active in
mouse embryo fibroblasts lacking the
NF1 tumor suppressor compared with
wild-type counterparts. Consistent with
HSF1 function in regulating survival
through increased chaperone expression
in aneuploid cancer cells (Kim et al.,
2009), they found rohibitin to be more
potent against aneuploid cells compared
to near-diploid cancer cells and healthy
cells. Interestingly, inhibiting translation
initiation with rohibitin proved more
‘‘cancer-selective’’ than blocking transla-
tion elongation with cycloheximide in
these models. Cancer selectivity was
confirmed in broader cell panel pro-
filing. Finally, Santagata et al. (2013)
demonstrated impressive antitumor
activity for rohibitin in vivo by using a
sensitive acute myeloid leukemia cell
line growing as a tumor xenograft in
immunocompromised mice. Modulation
of HSF1-regulated genes and glucose
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Previewsuptake again supported an HSF1-medi-
ated mechanism and represented poten-
tial biomarkers for future translational
studies.
Overall, Santagata et al. (2013) have
established an important regulatory link
between the translation pathway and
HSF1 that allows cancer cells to repro-
gram the cancer transcriptome to accom-
modate the essential increase in protein
production, including the switch to aero-
bic glycolysis required to meet the
biosynthetic needs of malignant growth,
especially the massive energy demands
of translation. Furthermore, targeting
translation initiation with rocaglates
blocks HSF1 activation via EIF4 inhibition
and thereby reverses malignant transcrip-
tional reprogramming, disables the glyco-
lytic switch, removes cytoprotective
chaperones, and inhibits tumor growth.
So what is next? There remain many
unanswered questions. What is the pre-
cise molecular mechanism that links pro-
tein translation to HSF1 activation? Does
it involve the translation of a factor
required for HSF1 activity?Might it involve
the production of a key protein involved in
one of the many posttranslational modifi-
cations regulating HSF1? Does blocking
the translation of oncogenic mRNAs with
long highly structured 50UTRs that require
EIF4A-dependent unwinding contribute
to the anticancer effects seen? Intrigu-
ingly, the results obtained here for cancer
cells contrast those in yeast where the
HSF1-mediated stress response is acti-
vated by the translational stress resulting
from stalled rather than enhanced proteinsynthesis (Brandman et al., 2012). Coordi-
nating the malignant proteome and tran-
scriptome likely involves a highly complex
network of interactions of which HSF1 is
but one—albeit very important—regulato-
ry element. It would be fascinating to
know how the reported effects connect
with another critical proteostasis
pathway hijacked in cancer: the unfolded
protein response in which inadequate
protein folding leads to the beneficial
reprogramming of translation and tran-
scription to promote survival. Other key
questions include: why does inhibition of
protein initiation deliver a more selec-
tive anticancer effect than blockade of
protein elongation? How might cancer
cells develop resistance to EIF4A
inhibition? Global proteomic analysis
could be used alongside transcriptome
profiling to ask whether a subset of pro-
teins is regulated as opposed to a global
effect.
Although inhibiting translational initia-
tion appears to be a promising approach,
it is clear that the effects will be very pleio-
tropic. Ongoing research will continue to
reveal the proximal regulators of the
multifaceted and megalomaniac func-
tions of HSF1 in cancer. This could help
us to develop a range of yet more selec-
tive inhibitors of HSF1 function. Given
the widespread resistance seen with
drugs targeting single oncogene addic-
tion and synthetic lethality (Al-Lazikani
et al., 2012), new therapeutics selectively
targeting such essential regulators of core
malignancy programs like HSF1 are
urgently needed.Cancer Cell 24ACKNOWLEDGMENTS
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